

DC Lung Cancer Conference 2024



October 19, 2024

Grand Hyatt Washington | Washington, D.C.

Course Director:

Stephen V. Liu, MD

MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, D.C.



Endorsed by:



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

#DCLUNG24

Continuing Education Credit Information

Course Description

This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on modern bronchoscopy, proton beam radiation, minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over use of emerging biomarkers to guide treatment of advanced NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

Learning Objectives

- Explain the significance and use of patient centered communications on the patient and family experience.
- Identify the survival benefit of CT screening for lung cancer.
- Discuss the current application of liquid biopsy (or ctDNA analysis).
- Describe the methods used for biomarker testing in lung cancer.
- Explain the approved use of neoadjuvant and perioperative immunotherapy for patients with resectable lung cancer.
- Debate the use of targeted therapy for patients with resected EGFR mutant non-small cell lung cancer.
- Describe current standard care for advanced mesothelioma.
- Describe the best initial therapy for advanced small cell lung cancer (SCLC).
- Describe the benefit of immunotherapy in the treatment of small cell lung cancer.
- Discuss management of immune-mediated toxicities.
- Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
- Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
- Name the approved targeted agent for HER2 mutant NSCLC.
- List the currently approved targeted options for patients with MET exon 14 mutant lung cancer.
- Integrate a team-based approach in the care of patients with lung cancer.

Target Audience

This conference is intended for medical oncologists, pathologists, pulmonologists, radiation oncologists, radiologists, surgeons, residents, fellows, physician assistants, nurses, pharmacists, medical students, allied health professionals, and other members of the healthcare team interested in the management of lung cancer.

For updated program information, please visit [MedStarHealth.org/DC Lung24](https://www.medstarhealth.org/DC Lung24)

Continuing Education Credit Information

Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 6.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 6.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



American Board of Internal Medicine MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC Participation Threshold: Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 6.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: This activity is approved for 6.75 contact hours. This learning activity is knowledge-based. The Universal Activity Number for this program is UAN# JA4008151-0000-24-028-L05-P.

Additional Information

Attention Physician Learners: To ensure accurate CME credit data reporting to participating state medical licensing boards/certifying boards, please log into CloudCME and click on My CE / Profile to review and update your profile with the following details: your full name, state of licensure (including number and expiration date), and your birth month and day. Additionally, please remember to check the box at the bottom of the profile screen to grant permission for us to report your completion data to ACCME and participating licensing/certifying boards. Questions? Email medstarceapplications@email.sitel.org

For updated program information, please visit [MedStarHealth.org/DC Lung24](https://www.medstarhealth.org/DC Lung24)

Course Director



Stephen V. Liu, MD

Director, Thoracic Medical Oncology
Head, Developmental Therapeutics
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Associate Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Faculty

Nagla F. Abdel Karim, MD

Director of Phase I Program and Thoracic
Medical Oncologist
Inova Health System
Fairfax, VA
Professor, Medicine
University of Virginia
Charlottesville, VA

Charu Aggarwal, MD, MPH

Director, Precision Oncology Innovation
Penn Center for Cancer Care Innovation
Leslye Heisler Professor of Lung Cancer
Excellence
University of Pennsylvania Perelman School of
Medicine
Philadelphia, PA

Eric D. Anderson, MD

Director, Interventional Pulmonology
MedStar Georgetown University Hospital
Professor, Clinical Medicine
Division of Pulmonary, Critical Care &
Sleep Medicine
Georgetown University Medical Center
Washington, D.C.

Amin Benyounes, MD

Thoracic Medical Oncologist
Inova Schar Cancer Institute
Falls Church, VA

Hossein Borghaei, DO, MS

Chief, Thoracic Medical Oncology
Professor, Hematology/Oncology
The Gloria and Edmund M. Dunn Chair in
Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, PA

Stephen R. Broderick, MD, MPHS

Thoracic Surgeon
Sibley Memorial Hospital
Washington, D.C.
Associate Professor, Surgery
Johns Hopkins University School of Medicine
Baltimore, MD

Tina Cascone, MD, PhD

Associate Professor
Director of Translational Research
Department of Thoracic & Head and Neck
Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Terri Conneran

Founder
KRAS Kickers
Charlotte, NC

Alissa J. Cooper, MD

Thoracic Medical Oncologist
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Ibiayi Dagogo-Jack, MD

Thoracic Medical Oncologist
Massachusetts General Hospital
Assistant Professor, Medicine
Harvard Medical School
Boston, MA

Alexander E. Drilon, MD

Chief, Early Drug Development Service
Associate Attending Physician, Thoracic
Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Faculty

Narjust Florez, MD

Director, Smoking Cessation Program
Associate Director, Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Brigham Cancer Center
Assistant Professor, Medicine
Harvard Medical School
Boston, MA

Marina Chiara Garassino, MBBS

Director, Thoracic Oncology Program
Professor, Medicine
The University of Chicago Medicine
Chicago, IL

Ryan D. Gentzler, MD, MS

Medical Oncologist, Thoracic Oncology
Associate Professor, Medicine
University of Virginia Comprehensive Cancer Center
Charlottesville, VA

Brinda Gupta, MD

Hematology & Oncology Fellow
MedStar Georgetown University Hospital
Washington, D.C.

Chul Kim, MD, MPH

Thoracic Medical Oncologist
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Associate Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Ticiana Leal, MD

Director, Thoracic Oncology Program
Department of Hematology and Medical Oncology
Associate Professor, Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA

Matthew C. Lee, MD, MPH

Assistant Professor, Medical Oncologist
Montefiore Einstein Comprehensive Cancer Center (MECCC)
Bronx, NY

Natasha B. Leighl, MD, MMSc

Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor, Medicine
University of Toronto
Toronto, Canada

Jessica J. Lin, MD

Thoracic Medical Oncologist
Center for Thoracic Cancers
Henri and Belinda Termeer Center for Targeted Therapies
Massachusetts General Hospital
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Jonathan W. Lischalk, MD

Medical Director, NYU Langone Manhattan Cyberknife Center
Director, Research Radiation Oncology
Associate Professor, Radiation Oncology
NYU Langone Perlmutter Cancer Center
NYU Grossman Long Island School of Medicine
New York, NY

Christine M. Lovly, MD, PhD

Associate Professor of Medicine
Division of Hematology-Oncology
Ingram Associate Professor, Cancer Research
Vanderbilt University Medical Center
Vanderbilt Ingram Cancer Center
Nashville, TN

Laura Macke, MS, FNP-C, AOCNP

Nurse Practitioner, Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, D.C.

Marc Margolis, MD

Chief, Thoracic Surgery
MedStar Georgetown University Hospital
Washington, D.C.

Jennifer A. Marks, MD

Affiliate Staff
Brigham and Women's Hospital
Department of Medicine
Division of Medical Oncology
Boston, MA

Faculty

Sandip P. Patel, MD

Professor, Medical Oncologist
University of California San Diego
San Diego, CA

Zofia Piotrowska, MD, MHS

Thoracic Medical Oncologist
Massachusetts General Hospital
Assistant Professor, Medicine
Harvard Medical School
Boston, MA

Isabel Preeshagul, DO, MBS

Thoracic Medical Oncologist
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Joshua E. Reuss, MD

Thoracic Medical Oncologist
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Assistant Professor, Medicine
Georgetown University Medical Center
Washington, D.C.

Christian D. Rolfo, MD, PhD, MBA, Dr.hc.

Director Division, Medical Oncology
Associate Director, Early Phase Clinical Trials
Professor, Medicine
Ohio State University Comprehensive Cancer Center
The James Cancer Hospital
Columbus, OH

Samuel Rosner, MD

Thoracic Oncologist
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Assistant Professor, Medicine
University of Maryland School of Medicine
Baltimore, MD

Susan C. Scott, MD, MA

Thoracic Medical Oncologist
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Assistant Professor, Oncology
Johns Hopkins University School of Medicine
Baltimore, MD

Misty D. Shields, MD, PhD

Assistant Professor, Clinical Medicine
Indiana University School of Medicine
Indianapolis, IN

Jonathan Spicer, MD

Director, Thoracic Oncology Biobank
Medical Director, McGill Thoracic Oncology Network
Program Director, Advanced Thoracic and Upper GI Surgical Oncology Fellowship
Associate Professor, Surgery
McGill University
Montreal, Canada

Brendon M. Stiles, MD

Associate Director, Surgical Services
Montefiore-Einstein Comprehensive Cancer Center
Professor and Chief, Thoracic Surgery and Surgical Oncology
Albert Einstein College of Medicine
Montefiore Medical Center
New York, NY

Irina G. Veytsman, MD

Section Director, Hematology and Oncology
Medical Oncologist
MedStar Washington Hospital Center
MedStar Georgetown Cancer Institute
Washington, D.C.

Liza C. Villaruz, MD

Medical Oncologist
Co-Leader, Immunotherapy and Drug Development Center (IDDC)
Associate Professor, Medicine
UPMC Hillman Cancer Center
Pittsburgh, PA

Agenda

7:30 a.m. Registration, Continental Breakfast, and Visit the Exhibits

8:00 a.m. Welcome Remarks
Stephen V. Liu, MD

SESSION I: DIAGNOSIS

Moderator: Samuel Rosner, MD

8:05 a.m. The Value of Research: A Patient Perspective
Terri Conneran

8:15 a.m. Lung Cancer Screening
Eric D. Anderson, MD

8:25 a.m. The Ever-Evolving World of Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)
Christine M. Lovly, MD, PhD

8:35 a.m. Liquid Biopsy: Now and the Future
Natasha B. Leighl, MD, MMSc

8:45 a.m. Potential for Liquid Biopsy in Early Stage NSCLC
Christian D. Rolfo, MD, PhD, MBA, Dr.hc.

8:55 a.m. Artificial Intelligence: Actual Impact?
Sandip P. Patel, MD

9:05 a.m. Session I Panel Discussion
Moderator: Samuel Rosner, MD
Panelists: E. Anderson; T. Conneran; N. Leighl; C. Lovly; S. Patel; C. Rolfo

9:20 a.m. Coffee Break and Visit the Exhibits

SESSION II: EARLY-STAGE NSCLC

Moderator: Stephen R. Broderick, MD, MPHS

9:35 a.m. Extent of Resection: Is Less More?
Marc Margolis, MD

9:45 a.m. SBRT for Early-Stage NSCLC
Jonathan W. Lischalk, MD

9:55 a.m. Before and After, Molecular Targets in Resectable NSCLC
Narjust Florez, MD

10:05 a.m. Adjuvant Immunotherapy: Who Benefits?
Ryan D. Gentzler, MD, MS

10:15 a.m. Neoadjuvant and Perioperative Immunotherapy
Tina Cascone, MD, PhD

10:25 a.m. Patient Selection for Neoadjuvant Therapy
Jonathan Spicer, MD

10:35 a.m. Treating Unresectable Stage III NSCLC
Charu Aggarwal, MD, MPH

10:45 a.m. Session II Panel Discussion
Moderator: Stephen R. Broderick, MD, MPHS
Panelist: C. Aggarwal; T. Cascone; N. Florez; R. Gentzler; J. Lischalk; M. Margolis; J. Spicer

11:00 a.m. Debate Introduction
Isabel Preeshagul, DO, MBS

11:05 a.m. Resected Stage III Anaplastic Lymphoma Kinase (ALK) NSCLC: Adjuvant TKI Alone
Joshua E. Reuss, MD

11:15 a.m. Adjuvant Chemotherapy + TKI
Marina Chiara Garassino, MBBS

11:25 a.m. Lunch and Visit the Exhibits

11:55 a.m. Immunotherapy in Practice: A Compelling Case-Based Discussion Examining Actual Patients with Advanced NSCLC
Abhirami Vivekanandarajah, MD
Lunch Symposium sponsored by Regeneron
This symposium is not certified for continuing education credit.

12:40 p.m. Dessert and Visit the Exhibits

Agenda

SESSION III: IMMUNOTHERAPY AND ADVANCED THORACIC CANCERS

Moderator: TBD

- 1:10 p.m. **Emerging Systemic Strategies for Mesothelioma**
Ibiayi Dagogo-Jack, MD
- 1:20 p.m. **TTFields for Mesothelioma and NSCLC**
Ticiana Leal, MD
- 1:30 p.m. **SCLC: Current Standards and Emerging Agents**
Misty D. Shields, MD, PhD
- 1:40 p.m. **Dual Checkpoint for NSCLC: What's the CTLA4-11**
Hossein Borghaei, DO, MS
- 1:50 p.m. **Optimal Duration of Immunotherapy for NSCLC**
Matthew C. Lee, MD, MPH
- 2:00 p.m. **Immunotherapy Toxicity for Daily Practice**
Laura Macke, MS, FNP-C, AOCNP
- 2:10 p.m. **Surgery and Stage IV NSCLC: When, Why, and for Whom?**
Brendon M. Stiles, MD
- 2:20 p.m. **Session III Panel Discussion**
Panelists: H. Borghaei; I. Dagogo-Jack; T. Leal; M. Lee; L. Macke; M. Shields, B. Stiles
- 2:35 p.m. **Afternoon Break & Visit the Exhibits**

SESSION IV: TARGETED THERAPY FOR ADVANCED NSCLC

Moderator: Nagla F. Abdel Karim, MD

- 2:45 p.m. **Defining the Role of Antibody-Drug Conjugates (ADCs) in NSCLC**
Alissa J. Cooper, MD
- 2:55 p.m. **RET: Past, Present, and Future**
Alexander E. Drilon, MD

- 3:05 p.m. **First Line Options for ALK/ROS1 NSCLC**
Jessica J. Lin, MD
- 3:15 p.m. **Targeting ROS1 in NSCLC**
Liza C. Villaruz, MD
- 3:25 p.m. **Strategies for KRAS Mutant NSCLC**
Jennifer A. Marks, MD
- 3:35 p.m. **Session IV Panel Discussion**
Moderator: Nagla F. Abdel Karim, MD
Panelist: A. Drilon; A. Cooper; J. Lin; J. Marks; L. Villaruz
- 3:45 p.m. **Afternoon Break & Visit the Exhibits**

SESSION V: TARGETED THERAPY FOR ADVANCED NSCLC #2

Moderator: Brinda Gupta, MD

- 3:55 p.m. **First-Line EGFR: Which Option is Best?**
Susan C. Scott, MD, MA
- 4:05 p.m. **Exon 20 (HER2 and EGFR): Evolving Options**
Chul Kim, MD, MPH
- 4:15 p.m. **What's Next for EGFR? Overcoming Resistance**
Zofia Piotrowska, MD, MHS
- 4:25 p.m. **NTRK and NRG1: Needles in the Haystack**
Amin Benyounes, MD
- 4:35 p.m. **Managing BRAF and METex14 Mutant NSCLC**
Irina G. Veytsman, MD
- 4:45 p.m. **Session V Panel Discussion**
Moderator: Brinda Gupta, MD
Panelist: A. Benyounes; C. Kim; Z. Piotrowska; S. Scott, I. Veytsman
- 4:55 p.m. **Closing Remarks**
Stephen V. Liu, MD

Registration Information

REGISTRATION TYPE	NOW THROUGH JULY 19	JULY 20 TO OCTOBER 19
Physician	\$175	\$200
IASLC Member	\$140	\$140
Resident or Fellow	\$0	\$0
Physician Assistant	\$100	\$125
Nurse Practitioner	\$100	\$125
Nurse	\$100	\$125
Pharmacist	\$100	\$125
Allied Health Professional	\$100	\$125
Industry Professional	\$250	\$275

Online Registration Preferred

Please visit **MedStarHealth.org/DCLung24** for updated program and registration information. We are unable to accept registrations or cancellations by telephone.

All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at MedStarCPE@MedStar.net or (833) 731-1273.

Cancellation Policy

Cancellations made in writing by September 7, 2024 will be subject to a 50% penalty. No refunds will be given after September 7, 2024. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Venue Information

Grand Hyatt Washington

1000 H Street NW | Washington, D.C. 20001
(202) 582-1234



For grant information please contact Ada Guo at ada.guo@medstar.net
For exhibit information please contact Elizabeth Romano at elizabeth.s.romano@medstar.net